• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is SSRI Efficacy Real, or Just a Placebo Response?

Is SSRI Efficacy Real, or Just a Placebo Response?

May 1, 2018
Adam Strassberg, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Hieronymus F et al, Molecular Psychiatry 2017. doi:10.1038/mp.2017.147

Over the last several years, there’s been a lively debate about the efficacy of antidepressants. Meta-analyses have shown that antidepressants do outperform placebo in most studies. However, active medications cause more side effects than placebo pills. Thus, it’s possible that side effects lead patients to accurately guess that they’ve been assigned to the active drug group, and this positive expectancy alone could underlie any supposed efficacy of the drug.

But how would you structure a study to resolve this problem? You can’t randomly assign patients to the active medication with side effects vs the same active medication without side effects. So, researchers have resorted to the artful use of statistical methods. One of these is called a “mega-analysis.” In a mega-analysis, you combine the results of independent studies using data from the individual subjects. This differs from the more common meta-analysis, which combines the results of independent studies using summary data from groups of people.

In a new mega-analysis, the authors reviewed all industry-sponsored, FDA-registered, placebo-controlled trials of paroxetine and citalopram in adults with major depressive disorder. 2,759 patients were included from the paroxetine trials, and 585 patients formed the citalopram trials. The purpose was to compare the response of patients who reported side effects vs those who were side effect–free.

Focusing on the mood item of the Hamilton Depression Rating Scale (HDRS) as the outcome measure, researchers found that among patients who reported no side effects, patients assigned to paroxetine or citalopram did significantly better than those assigned to placebo (p < 0.001). Furthermore, looking at the entire sample, there were no significant differences in the reductions in the HDRS-17 depressed mood item at 6 weeks for paroxetine treatment with or without side effects, and for citalopram treatment with or without side effects.

TCPR’s Take
This study supports the hypothesis that both citalopram and paroxetine have genuine antidepressant effects caused by their pharmacodynamic properties, and more than just placebo effects.
General Psychiatry
Adam Strassberg, MD.

Can Mindfulness-Based Stress Reduction Affect Symptom Outcomes in Older Adults?

More from this author
www.thecarlatreport.com
Issue Date: May 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Anxiety, TCPR, May 2018
Benzodiazepines for Anxiety: Where They Fit In
Anxious Distress: A New DSM Diagnosis
Neurofeedback and Adult ADHD
Is SSRI Efficacy Real, or Just a Placebo Response?
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.